A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Cevidoplenib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 13 Aug 2019 Status changed from planning to recruiting.
- 07 Jun 2018 New trial record
- 03 Jun 2018 According to the Genosco media release, company expects to initiate this trial in 2018.